Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.29 USD
Change Today +0.01 / 3.57%
Volume 19.9K
CTTC On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).

calmare therapeutics inc (CTTC) Snapshot

Open
$0.28
Previous Close
$0.28
Day High
$0.33
Day Low
$0.28
52 Week High
05/6/15 - $0.49
52 Week Low
09/29/14 - $0.08
Market Cap
8.2M
Average Volume 10 Days
16.9K
EPS TTM
$-0.15
Shares Outstanding
28.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CALMARE THERAPEUTICS INC (CTTC)

Related News

No related news articles were found.

calmare therapeutics inc (CTTC) Related Businessweek News

No Related Businessweek News Found

calmare therapeutics inc (CTTC) Details

Calmare Therapeutics Incorporated, a biotechnology company, provides distribution, patent and technology transfer, sales, and licensing services in the United States. The company operates as a licensed distributor of the Calmare, a non-invasive pain therapy medical device to treat neuropathic and cancer-derived pain, as well as rents Calmare medical devices to end-users. It also identifies and commercializes technologies in life sciences, including medical testing, diagnostics, pharmaceuticals, biotechnologies, medical devices, and other medical or biological applications; physical sciences, such as chemical, display, and environmental applications; electronics comprising communications, semiconductors, internet related, e-commerce, and consumer electronics applications; and nanotechnologies, including the manipulation of microscopic particles into useful arrangements, and smart or novel materials. The company markets technologies and products through contacts in research and development, legal firms, corporations, seminars, and trade shows. It serves product inventors, manufacturers, and distributors. The company was formerly known as Competitive Technologies, Inc. and changed its name to Calmare Therapeutics Incorporated in August 2014. Calmare Therapeutics Incorporated was founded in 1968 and is based in Fairfield, Connecticut.

calmare therapeutics inc (CTTC) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $270.0K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $83.1K
Compensation as of Fiscal Year 2014.

calmare therapeutics inc (CTTC) Key Developments

Calmare Therapeutics Incorporated Wins Preliminary Three-Month Extension of its General Services Administration Military Contract

Calmare Therapeutics Incorporated has been awarded a preliminary three-month extension of its General Services Administration military contract (V797P-4300B). First awarded in 2010, the company's contract extension is designed to continue the streamlined procurement process for U.S. military personnel and their families and institutional customers across the globe who acquire Calmare Pain Therapy Devices and its consumables.

Calmare Therapeutics Incorporated Announces Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Calmare Therapeutics Incorporated announced consolidated earnings results for the fourth quarter and full year ended December 31, 2014. Revenue from the sale and shipment of the Calmare pain therapy devices (Devices) for the quarter ended December 31, 2014 decreased 52% or $119,000 to $108,000 as compared with $227,000 for the quarter ended December 31, 2013. This is largely attributable to the cyclicality and historically sales slow-down the company has witnessed over the last four years with respect to Device sales and its related consumables in the fourth quarter. Net loss for the quarter ended December 31, 2014 increased to $645,000 or $0.03 per basic and diluted share as compared with a net loss of $611,000 or $0.03 per basic and diluted share for the quarter ended December 31, 2013. For the year, the company reported operating loss of $2,229,783 compared to $2,520,739 a year ago. Loss before income taxes was $3,410,899 compared to $2,672,154 a year ago. Net loss was $3,410,899 compared to $2,672,154 a year ago. Basic and diluted loss per share was $0.15 compared to $0.16 a year ago. Net cash used in operating activities was $1,061,683 compared to $1,566,413 a year ago. Purchases of property and equipment were $45,581. Revenue from the sale and shipment of the Calmare pain therapy devices (Devices) for the year ended December 31, 2014 increased 60% or $392,000 to $1,045,000 as compared with $653,000 for the year-ended December 31, 2013.

Calmare Therapeutics Incorporated, Q4 2014 Earnings Call, Jul 01, 2015

Calmare Therapeutics Incorporated, Q4 2014 Earnings Call, Jul 01, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CTTC:US $0.29 USD +0.01

CTTC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CTTC.
View Industry Companies
 

Industry Analysis

CTTC

Industry Average

Valuation CTTC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.7x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CALMARE THERAPEUTICS INC, please visit www.calmaretherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.